Bio-Rad Laboratories, Inc. reported a challenging first-quarter 2026, with a net income loss of $527.1 million despite a slight revenue increase of 1.1%. The company's earnings growth is projected to decline by nearly 10%, raising concerns amid a fluctuating stock price currently at $247.53. RBC Capital reinstated an Outperform rating with a price target of $320.00, but rising short interest and mixed investor sentiment complicate the outlook.
“Bio-Rad Laboratories, Inc. · is · a global leader in developing, manufacturing, and marketing products · true”
“Bio-Rad Laboratories, Inc. · has been focused on · quality and customer service · over 70 years”
“Bio-Rad Laboratories, Inc. · trades on · NYSE · BIO”
“Bio-Rad Laboratories, Inc. · reported · first-quarter 2026 financial results · true”
“Bio-Rad Laboratories, Inc. · engages in · the development, manufacturing, and marketing of a portfolio of instruments, systems, reagents, and consumables”
“Bio-Rad Laboratories · operates through · the segments Life Science and Clinical Diagnostics”
“Bio-Rad Laboratories · has · CEO · Norman D. Schwartz”
“Bio-Rad Laboratories · has · employees · 7,450”
“Bio-Rad Laboratories · is headquartered in · Hercules, California”
“Bio-Rad Laboratories · is a · global provider of life science research and clinical diagnostic products”
“Bio-Rad Laboratories · was founded in · 1952”
“Bio-Rad Laboratories · is headquartered in · Hercules, California”
